Ultragenyx Pharmaceutical - RARE Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RARE shares.
View RARE analyst ratings or view top-rated stocks.

12 brokerages have issued twelve-month price objectives for Ultragenyx Pharmaceutical's stock. Their RARE share price forecasts range from $50.00 to $142.00. On average, they predict the company's stock price to reach $91.69 in the next twelve months. This suggests a possible upside of 99.6% from the stock's current price.
View analysts price targets for RARE or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $46.33 at the start of the year. Since then, RARE stock has decreased by 0.8% and is now trading at $45.94.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our RARE earnings forecast.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.35. The biopharmaceutical company had revenue of $81.65 million for the quarter, compared to analyst estimates of $78.16 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 84.14% and a negative net margin of 197.47%. During the same quarter in the previous year, the firm posted ($1.13) EPS.

41 employees have rated Ultragenyx Pharmaceutical Chief Executive Officer Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.49%), Emerald Mutual Fund Advisers Trust (0.36%), Assenagon Asset Management S.A. (0.23%), Peregrine Capital Management LLC (0.21%), Pinnacle Associates Ltd. (0.18%) and Pinnacle Associates Ltd. (0.18%). Insiders that own company stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RARE stock can currently be purchased for approximately $45.94.

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.22 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($9.74) on an earnings per share basis.

The company employs 1,119 workers across the globe.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for the company is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.